Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Emerging biomarkers and metabolomics for assessing toxic nephropathy and acute kidney injury (AKI) in neonatology.

Mussap M, Noto A, Fanos V, Van Den Anker JN.

Biomed Res Int. 2014;2014:602526. doi: 10.1155/2014/602526. Review.

2.

Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity.

Buness A, Roth A, Herrmann A, Schmitz O, Kamp H, Busch K, Suter L.

PLoS One. 2014 May 16;9(5):e97249. doi: 10.1371/journal.pone.0097249.

3.

The current status of biomarkers for predicting toxicity.

Campion S, Aubrecht J, Boekelheide K, Brewster DW, Vaidya VS, Anderson L, Burt D, Dere E, Hwang K, Pacheco S, Saikumar J, Schomaker S, Sigman M, Goodsaid F.

Expert Opin Drug Metab Toxicol. 2013 Nov;9(11):1391-408. doi: 10.1517/17425255.2013.827170. Review.

4.

In situ mass spectrometry imaging and ex vivo characterization of renal crystalline deposits induced in multiple preclinical drug toxicology studies.

Nilsson A, Forngren B, Bjurström S, Goodwin RJ, Basmaci E, Gustafsson I, Annas A, Hellgren D, Svanhagen A, Andrén PE, Lindberg J.

PLoS One. 2012;7(10):e47353. doi: 10.1371/journal.pone.0047353.

5.

Proteomic candidate biomarkers of drug-induced nephrotoxicity in the rat.

Rouse R, Siwy J, Mullen W, Mischak H, Metzger J, Hanig J.

PLoS One. 2012;7(4):e34606. doi: 10.1371/journal.pone.0034606.

6.

Emergence of biomarkers in nephropharmacology.

Khan E, Batuman V, Lertora JJ.

Biomark Med. 2010 Dec;4(6):805-14. doi: 10.2217/bmm.10.115. Review.

7.

Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity.

Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S.

Biometals. 2011 Apr;24(2):239-58. doi: 10.1007/s10534-010-9389-y.

Items per page

Supplemental Content

Support Center